MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 328305 | Name: Terazosin HCl hydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Terazosin, also known as Hytrin and A-45975, is an adrenergic receptor antagonist used to treat hypertension and benign prostatic hypertrophy.

Chemical Structure

Terazosin HCl hydrate
Terazosin HCl hydrate
CAS#70024-40-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 328305

Name: Terazosin HCl hydrate

CAS#: 70024-40-7 (HCl)

Chemical Formula: C19H30ClN5O6

Exact Mass: 387.1907

Molecular Weight: 459.93

Elemental Analysis: C, 49.62; H, 6.57; Cl, 7.71; N, 15.23; O, 20.87

Price and Availability

Size Price Availability Quantity
100mg USD 350.00
200mg USD 550.00
500mg USD 950.00
1g USD 1,650.00
2g USD 2,150.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
63074-08-8 (free base) 70024-40-7 (HCl)
Synonym
Terazosin; Terazosin hydrochloride; Hytrin; A-45975; A 45975; A45975; Terazosin HCl hydrate; Terazosin HCl dihydrate
IUPAC/Chemical Name
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone hydrochloride dihydrate
InChi Key
NZMOFYDMGFQZLS-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2
SMILES Code
O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OCCC4.[H]Cl.[H]O[H].[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 70024-40-7 (Terazosin hydrochloride) 63590-64-7 (Terazosin)

Preparing Stock Solutions

The following data is based on the product molecular weight 459.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang J, Yan D, Liang K, Xu Z. A randomized controlled trial of levofloxacin, terazosin, and combination therapy in patients with category III chronic prostatitis/chronic pelvic pain syndrome. Int Urol Nephrol. 2016 Jan;48(1):13-8. doi: 10.1007/s11255-015-1147-1. Epub 2015 Nov 17. PubMed PMID: 26577998. 2: Vidal Margenat A, Ferrando-Castagnetto F, Martínez F, Lluberas N, Vignolo G. Myocardial infarction induced by oral terazosin in a patient with predisposing structural cardiomyopathy: case report. Medwave. 2016 Jun 28;16(5):e6480. doi: 10.5867/medwave.2016.05.6480. English, Spanish. PubMed PMID: 27392141. 3: Nirmalani-Gandhy A, Sanchez D, Catalano G. Terazosin for the treatment of trauma-related nightmares: a report of 4 cases. Clin Neuropharmacol. 2015 May-Jun;38(3):109-11. doi: 10.1097/WNF.0000000000000077. PubMed PMID: 25970279. 4: Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M. Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial. Int Braz J Urol. 2013 Nov-Dec;39(6):832-40. doi: 10.1590/S1677-5538.IBJU.2013.06.09. PubMed PMID: 24456787. 5: Guo X, Wu H, Guo S, Shi Y, DU J, Zhu P, DU L. Highly Sensitive Fluorescence Methods for the Determination of Alfuzosin, Doxazosin, Terazosin and Prazosin in Pharmaceutical Formulations, Plasma and Urine. Anal Sci. 2016;32(7):763-8. doi: 10.2116/analsci.32.763. PubMed PMID: 27396658. 6: Ghaleiha A, Shahidi KM, Afzali S, Matinnia N. Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: a randomized controlled trial. Int J Psychiatry Clin Pract. 2013 Feb;17(1):44-7. doi: 10.3109/13651501.2012.687449. Epub 2012 Jun 26. PubMed PMID: 22731399. 7: Liu M, Zhang D, Yang M, Zhao T, Wang X, Zhang Y, Han J, Liu H. Pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. Chirality. 2012 Dec;24(12):1047-50. doi: 10.1002/chir.22095. Epub 2012 Aug 9. PubMed PMID: 22887707. 8: Chen X, Zhao C, Li X, Wang T, Li Y, Cao C, Ding Y, Dong M, Finci L, Wang JH, Li X, Liu L. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. Nat Chem Biol. 2015 Jan;11(1):19-25. doi: 10.1038/nchembio.1657. Epub 2014 Nov 10. PubMed PMID: 25383758; PubMed Central PMCID: PMC4412158. 9: Mitropoulos D, Patris E, Deliconstantinos G, Kyroudi-Voulgari A, Anastasiou I, Perea D. Terazosin-induced alterations in catalase expression and lipid peroxidation in the rat seminal vesicles. Andrologia. 2013 Apr;45(2):128-34. doi: 10.1111/j.1439-0272.2012.01324.x. Epub 2012 Jun 26. PubMed PMID: 22731390. 10: Mago R, Thase ME, Rovner BW. Antidepressant-induced excessive sweating: clinical features and treatment with terazosin. Ann Clin Psychiatry. 2013 Aug;25(3):186-92. Epub 2013 May 1. PubMed PMID: 23638448.